Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05418296 · ClinicalTrials.gov registry record · NA

Assessing a Novel Virtual Environment That Assists With Activities of Daily Living

A NA study of Alzheimer Disease and Dementia, sponsored by mandy.

Completed
Registry status
NA
Development phase
38
Enrollment target
2
Study locations

NCT05418296: Completed NA study of Alzheimer Disease and Dementia, sponsored by mandy.

NCT05418296 is a NA study of Alzheimer Disease and Dementia that has completed, run by mandy. The registered enrollment target is 38 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05418296, a NA study of Alzheimer Disease and Dementia, has completed, sponsored by mandy.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
2
Study locations

Study Summary

This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.

Primary Outcome

The ADCS-ADL assesses the competence of patients with Alzheimer's Disease (AD) in basic and instrumental activities of daily living (ADLs). It can be completed by a caregiver in questionnaire format, or administered by a clinician/researcher as a structured interview with a caregiver. There are 19 questions. The minimum and maximum values are 0 - 54. A higher score means a better outcome.

Interventions

  • DEVICE A novel digital health device

Study Locations (2)

California

  • Bruceville Point Senior Living Community - Elk Grove
  • Elder Ashram - Oakland

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2022-06-09
Est. Completion 2023-10-30
Phase NA
mandy

1 total trials

What the finished NCT05418296 record still lists

NCT05418296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which A novel digital health device is the first listed.

NCT05418296 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05418296 about?

NCT05418296 is a clinical study titled "Assessing a Novel Virtual Environment That Assists With Activities of Daily Living". This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.

What is the current status of trial NCT05418296?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2022-06-09. Estimated completion is 2023-10-30.

What conditions does trial NCT05418296 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Neurodegenerative Diseases.

What interventions are being tested in trial NCT05418296?

The interventions under investigation include: A novel digital health device (DEVICE).

Who is sponsoring clinical trial NCT05418296?

This trial is sponsored by mandy, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05418296 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05418296's enrollment target sits among peer trials

38 234th of 306 higher than 72 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05418296, the US trial registry maintained by the National Library of Medicine. NCT05418296 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.